Altfest L J & Co. Inc. raised its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 9.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,138 shares of the biopharmaceutical company’s stock after buying an additional 4,254 shares during the period. Bristol-Myers Squibb makes up approximately 1.1% of Altfest L J & Co. Inc.’s holdings, making the stock its 17th largest position. Altfest L J & Co. Inc.’s holdings in Bristol-Myers Squibb were worth $2,726,000 as of its most recent filing with the SEC.
Other institutional investors have also added to or reduced their stakes in the company. Shayne & CO. LLC raised its position in shares of Bristol-Myers Squibb by 0.7% in the first quarter. Shayne & CO. LLC now owns 4,017 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 27 shares during the period. Founders Capital Management LLC raised its position in shares of Bristol-Myers Squibb by 0.7% in the first quarter. Founders Capital Management LLC now owns 4,097 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 29 shares during the period. Physicians Financial Services Inc. raised its position in shares of Bristol-Myers Squibb by 0.4% in the first quarter. Physicians Financial Services Inc. now owns 9,929 shares of the biopharmaceutical company’s stock valued at $540,000 after buying an additional 39 shares during the period. Pittenger & Anderson Inc. raised its position in shares of Bristol-Myers Squibb by 0.4% in the fourth quarter. Pittenger & Anderson Inc. now owns 9,650 shares of the biopharmaceutical company’s stock valued at $564,000 after buying an additional 40 shares during the period. Finally, Alpha Windward LLC raised its position in shares of Bristol-Myers Squibb by 0.9% in the first quarter. Alpha Windward LLC now owns 5,427 shares of the biopharmaceutical company’s stock valued at $295,000 after buying an additional 51 shares during the period. 69.68% of the stock is owned by institutional investors.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) traded down 0.64% on Wednesday, hitting $57.50. The stock had a trading volume of 7,881,340 shares. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $60.45. The company has a 50 day moving average price of $55.91 and a 200-day moving average price of $54.89. The stock has a market cap of $94.30 billion, a PE ratio of 21.00 and a beta of 1.17.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.01. The firm had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The business’s revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.69 EPS. On average, equities research analysts anticipate that Bristol-Myers Squibb Company will post $2.97 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 1st. Stockholders of record on Friday, July 7th were given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 2.71%. The ex-dividend date was Wednesday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is 56.73%.
Several equities analysts have weighed in on the company. Credit Suisse Group set a $58.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Wednesday. Cowen and Company set a $65.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. Vetr downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $63.81 target price on the stock. in a research report on Wednesday, August 9th. Finally, BidaskClub upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $62.12.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II bought 6,000 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The shares were purchased at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the transaction, the director now owns 18,000 shares of the company’s stock, valued at $1,006,920. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.23% of the stock is currently owned by corporate insiders.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with our FREE daily email newsletter.